Chemo Brain, or Loss of Mental Sharpness, Found to Have Biological Basis
Although up to 75% of cancer survivors experience altered mental function following treatment – often called “chemo brain” or “chemo fog”, doctors often believed that these effects were psychological, a form of depression. However, a new study, published in the Archives of Neurology, has Stanford Cancer Center researchers providing biological evidence that the effects are real, particularly for women who have undergone chemotherapy.
Cancer patients who complain of loss of mental sharpness are actually complaining about loss of prefrontal-executive function, the type of mental activity that includes the ability to selectively pay attention, work with information, and choose the appropriate response in a situation.
Shelli R. Kesler and colleagues scanned the prefrontal cortex of the brains of 25 breast cancer patients who had been treated with chemo, 19 breast cancer patients who had not had chemotherapy, and 18 healthy women. The researchers used functional magnetic resonance imaging (fMRI) while the women completed a brainteaser in which they tried to discern a pattern in a series of cards printed with geometric shapes. This test measures cognitive flexibility, or the ability to identify the best solution to a problem by testing several possibilities. The women also completed questionnaires to assess their own cognitive abilities.
Overall, both groups of breast-cancer patients showed less activity in the regions of the brain involved in executive function tasks than did the control group of health women. The chemotherapy-treated ladies displayed the least activity of any group in the parts of the brain associated with cognitive flexibility. These women made the most mistakes on the task on average, and took the most time to complete it.